The Cyclotron NetworkNarrow moat

Synektik (SNT) — moat facet

Synektik owns three of the five private cyclotrons in Poland, in a business that cannot be imported.

A cyclotron is expensive, needs a pharmaceutical licence and produces a product that decays too quickly to import. That combination makes radiopharmaceuticals a local business, and Synektik owns much of Poland's private capacity. Of nine cyclotrons in the country, four were bought and installed by public bodies and five belong to private companies, three of them to Synektik1. Its plants are in Kielce, Warsaw and Mszczonów2.

Cyclotrons in Poland3Synektik2Other private4PublicSynektik annual management board report, year to September 2025
A third of the country and most of the private capacity.

The network came partly by acquisition. Synektik bought Monrol Poland on 29 March 20183 and booked a bargain-purchase gain of 9,4 million złoty on it4, meaning it paid less than the fair value of what it acquired. Its own history in the field goes back further: it installed Poland's first commercial cyclotron for approved radiopharmaceuticals in 20125.

Owning three plants in different regions matters because the product has to reach scanners the same day. A PET centre needs a producer within driving distance, and a network can supply one plant's customers from another if a cyclotron is down.

The segment's EBITDA has roughly doubled in three years, from 7,6 million złoty in the year to September 20226 to 16,3 million złoty in 20247, as special products grew and fixed plant costs were spread over more doses.

The segment's EBITDA, 16,1 million złoty in the year to September 20258, is the return on that network.

Moat trajectory: Holding steady

No new plants disclosed; the network is unchanged.

The number that tests this moat
Reported
Radiopharmaceutical segment EBITDA, year to Sep 2025
16,1m zł (16,3m zł a year earlier)

The return on the cyclotron network.

Source: Synektik audited consolidated financial statements, year to September 2025 ↗
⚠ Threats to the moat
⚠ THREAT 01
Public Cyclotrons Need No Profit
Four of Poland's nine cyclotrons belong to public bodies that need earn nothing on them.
References
  1. ReportedOf nine cyclotrons in the country, four were bought and installed by public bodies and five belong to private companies, three of them to Synektik.
    Synektik annual management board report for the fiscal year to 30 September 2025 - description of the markets: robotic surgery in Poland, PET scanners, cyclotrons and NFZ-funded PET studies. — October 2024 - September 2025 · publ. December 2025 · source ↗
  2. ReportedIts plants are in Kielce, Warsaw and Mszczonów.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - radiopharmaceutical segment: plants, products, sales by type and quarterly results. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  3. ReportedSynektik bought Monrol Poland on 29 March 2018 and booked a bargain-purchase gain of 9,4 million złoty on it, meaning it paid less than the fair value of what it acquired.
    Synektik S.A. and Synektik Group interim condensed financial statements for 1 October 2025 - 30 June 2026 (third quarter of the fiscal year) - radiopharmaceutical segment: plants, products, sales by type and quarterly results. — October 2025 - June 2026 · publ. 5 August 2026 · source ↗
  4. ReportedSynektik bought Monrol Poland on 29 March 2018 and booked a bargain-purchase gain of 9,4 million złoty on it, meaning it paid less than the fair value of what it acquired.
    Synektik Group audited consolidated financial statements for the 21-month fiscal year 1 January 2017 - 30 September 2018 - including the bargain-purchase gain on Monrol Poland. — January 2017 - September 2018 · publ. 2019 · source ↗
  5. ReportedIts own history in the field goes back further: it installed Poland's first commercial cyclotron for approved radiopharmaceuticals in 2012.
    Synektik annual management board report for the fiscal year to 30 September 2025 - description of the markets: robotic surgery in Poland, PET scanners, cyclotrons and NFZ-funded PET studies. — October 2024 - September 2025 · publ. December 2025 · source ↗
  6. ReportedThe segment's EBITDA has roughly doubled in three years, from 7,6 million złoty in the year to September 2022 to 16,3 million złoty in 2024, as special products grew and fixed plant costs were spread over more doses.
    Synektik interim report for the fiscal year to 30 September 2022 - revenue, segments, installed base in Poland, Czechia and Slovakia, the first dedicated reimbursement and example tenders. — October 2021 - September 2022 · publ. November 2022 · source ↗
  7. ReportedThe segment's EBITDA has roughly doubled in three years, from 7,6 million złoty in the year to September 2022 to 16,3 million złoty in 2024, as special products grew and fixed plant costs were spread over more doses.
    Synektik interim report for the fourth quarter of the fiscal year to 30 September 2024 - revenue, operating profit, net profit, earnings per share, segments and dividends, with the year to September 2023 as comparative. — October 2023 - September 2024 · publ. November 2024 · source ↗
  8. ReportedThe segment's EBITDA, 16,1 million złoty in the year to September 2025, is the return on that network.
    Synektik Group audited consolidated financial statements for the fiscal year to 30 September 2025 (ESEF package) - revenue, costs, continuing and discontinued profit, earnings per share, segment note, cash flow. — October 2024 - September 2025 · publ. December 2025 · source ↗
Sources
Generated September 24, 2026